|

Diagnostic Performance of Spot Urine Sample for the Monoclonal Components Detection in Patients With Multiple Myeloma

RECRUITINGSponsored by Intergroupe Francophone du Myelome
Actively Recruiting
SponsorIntergroupe Francophone du Myelome
Started2022-05-18
Est. completion2026-05
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT05208086

Summary

The primary objective of the study is to evaluate at Day 1 Cycle 2, the detection sensitivity of the urinary monoclonal component on a spot urine sample, compared to the reference measurement on 24-hour urine, in patients with Multiple Myeloma.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* Patient with Multiple Myeloma
* Patient starting new treatment line, whatever the line is, but with at least 3 induction cycles
* Urine monoclonal component ≥ 200mg/24h

Exclusion Criteria:

Person under guardianship, trusteeship or deprived of freedom by a judicial or administrative decision

Conditions2

CancerMultiple Myeloma

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.